|
|
Volumn 333, Issue 6045, 2011, Pages 933-935
|
|
Drug developers finally take aim at a neglected Disease
a
a
NONE
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
ANTITRYPANOSOMAL AGENT;
BENZNIDAZOLE;
E 1224;
INSECTICIDE;
K 777;
NIFURTIMOX;
POSACONAZOLE;
RAVUCONAZOLE;
TIPIFARNIB;
UNCLASSIFIED DRUG;
ENZYME INHIBITOR;
DISEASE SEVERITY;
DRUG DEVELOPMENT;
LITERATURE REVIEW;
THEORETICAL STUDY;
ANOREXIA;
CHAGAS DISEASE;
DRUG INDUSTRY;
DRUG POTENCY;
DRUG SAFETY;
DRUG SCREENING;
DRUG SYNTHESIS;
FOOD AND DRUG ADMINISTRATION;
HEART FAILURE;
HUMAN;
NERVE INJURY;
NONHUMAN;
OSTEOPOROSIS;
PARASITE TRANSMISSION;
PRIORITY JOURNAL;
PSORIASIS;
SHORT SURVEY;
SKIN INFLAMMATION;
SOUTH AND CENTRAL AMERICA;
TROPICAL DISEASE;
TRYPANOSOMA CRUZI;
DRUG APPROVAL;
DRUG DEVELOPMENT;
DRUG EFFECT;
DRUG REPOSITIONING;
ENZYMOLOGY;
HIGH THROUGHPUT SCREENING;
NEGLECTED DISEASE;
NOTE;
CHAGAS DISEASE;
DRUG APPROVAL;
DRUG DISCOVERY;
DRUG EVALUATION, PRECLINICAL;
DRUG REPOSITIONING;
ENZYME INHIBITORS;
HIGH-THROUGHPUT SCREENING ASSAYS;
HUMANS;
NEGLECTED DISEASES;
TRYPANOCIDAL AGENTS;
TRYPANOSOMA CRUZI;
|
|
EID: 80051901437
PISSN: 00368075
EISSN: 10959203
Source Type: Journal
DOI: 10.1126/science.333.6045.933 Document Type: Short Survey |
|
Times cited : (34)
|
|
References (0)
|
